EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study

Ya Chen iD, Hongyu Liu, Nana Hu, Yanan Wang, Zhengyu Yang, Junqiang Zhang, Baohui Han iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6232 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ya Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Sci…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Acquired resistance represents a bottleneck to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) treatment in lung cancer. Our study aimed to explore the efficacy of antiangiogenic‐based therapy in osimertinib‐resistant NSCLC patients and assess the efficacy of anlotinib in vitro study.

Methods

Our multicenter study retrospectively collected 268 osimertinib‐resistant NSCLC patients with EGFR T790M mutation and explored the efficacy of anlotinib in patients and in vitro.

Results

PFS was significantly longer in the antiangiogenic‐based therapy group than in the immunotherapy group (HR: 0.71, p = 0.050) and the chemotherapy group (HR: 0.28, p = 0.001). Both the ORR and DCR of the antiangiogenic‐based group were higher than the immunotherapy group and the chemotherapy group. Subgroup analysis showed a trend of more benefits from the anlotinib‐based therapy than the bevacizumab‐based therapy in terms of PFS (HR: 0.63, p = 0.087) and OS (HR: 0.52, p = 0.063). In vitro assays verified that anlotinib alone or combined with osimertinib exerted potent cytotoxicity to T790M‐mutant H1975 cell line with acquired osimertinib resistance.

Conclusions

Our study suggested that antiangiogenic‐based therapy might improve PFS and OS in EGFR‐mutant NSCLC patients with acquired resistance to osimertinib. Moreover, anlotinib‐based therapy could be a promising effective treatment for this group of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRetrospective StudiesErbB ReceptorsMutationProtein Kinase InhibitorsAcrylamidesAniline CompoundsIndolesPyrimidinesQuinolines

Stichwörter der Autor:innen

anlotinibnon-small-cell lung cancerosimertinibresistance

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsosimertinibAcrylamidesAniline CompoundsIndolesPyrimidinesanlotinibQuinolines

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, China.
  • Department of Pulmonary, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Oncology, The Affiliated Hospital of QingDao University, QingDao, China.
  • Department of Respiratory and Clinical Care Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

ORCID-Profile: Ya Chen, Baohui Han

Förderung

  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Chen, Y., Liu, H., Hu, N., Wang, Y., Yang, Z., Zhang, J., & Han, B. (2023). Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study. Cancer Medicine. https://doi.org/10.1002/cam4.6232

Vancouver

Chen Y, Liu H, Hu N, Wang Y, Yang Z, Zhang J, et al. Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study. Cancer Medicine. 2023. doi:10.1002/cam4.6232

BibTeX
@article{Chen2023,
  author = {Chen, Ya and Liu, Hongyu and Hu, Nana and Wang, Yanan and Yang, Zhengyu and Zhang, Junqiang and Han, Baohui},
  title = {Survival benefit of anlotinib in T790M ‐positive non‐small‐cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6232}
}
Kostenlos starten →